Literature DB >> 18295387

Interpretation of the pharmacokinetics of ochratoxin A in blood plasma of rats, during and after acute or chronic ingestion.

Peter G Mantle1.   

Abstract

Experiments designed to reveal aspects of delivery of circulating ochratoxin A (OTA) to kidneys showed maximum plasma concentration within 3h of acute gavage, but this persisted for 4 days before decline. During long-term daily administration in feed, plasma values stabilised, proportional to dose and, for Fischer males, immediately followed an 8-10 day half-life upon ceasing OTA intake. In mature adult males, plasma OTA accumulated during the month after commencing daily intake of 100 microg. By comparison, in Dark Agouti males, lower steady state plasma values occurred and there was much shorter plasma OTA half-life (2-3 days). In F1 hybrid rats (Sprague Dawley x Fischer) males ingesting 100 microg OTA daily the steady state plasma value stabilised as in Fischer males, but females on the same diet accumulated OTA in plasma to nearly twice the value for males after only 5 months' exposure. Although OTA causes renal tumours in Fischer and Dark Agouti male rats in spite of marked difference in OTA elimination rates presently shown, understanding comparison of re-uptake along nephrons in rat and man in vivo is vital in applying rat toxicological data to assessment of risk of dietary OTA to humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295387     DOI: 10.1016/j.fct.2008.01.020

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  9 in total

Review 1.  Ochratoxins in feed, a risk for animal and human health: control strategies.

Authors:  Muzaffer Denli; Jose F Perez
Journal:  Toxins (Basel)       Date:  2010-05-13       Impact factor: 4.546

2.  Oncological outcomes in rats given nephrocarcinogenic exposure to dietary ochratoxin a, followed by the tumour promoter sodium barbital for life: a pilot study.

Authors:  Peter G Mantle; Miloslav Dobrota; Cheryl E Gillett; Edward W Odell; Sarah E Pinder
Journal:  Toxins (Basel)       Date:  2010-03-31       Impact factor: 4.546

3.  Pathological outcomes in kidney and brain in male Fischer rats given dietary ochratoxin A, commencing at one year of age.

Authors:  Peter G Mantle; Christopher C Nolan
Journal:  Toxins (Basel)       Date:  2010-05-13       Impact factor: 4.546

4.  Comments on "Ochratoxin A: In utero Exposure in Mice Induces Adducts in Testicular DNA. Toxins 2010, 2, 1428-1444"-Mis-Citation of Rat Literature to Justify a Hypothetical Role for Ochratoxin A in Testicular Cancer.

Authors:  Peter G Mantle
Journal:  Toxins (Basel)       Date:  2010-09-29       Impact factor: 4.546

5.  H NMR spectroscopy-based metabolomic assessment of uremic toxicity, with toxicological outcomes, in male rats following an acute, mid-life insult from ochratoxin a.

Authors:  Peter G Mantle; Andrew W Nicholls; John P Shockcor
Journal:  Toxins (Basel)       Date:  2011-05-26       Impact factor: 4.546

6.  Contribution of organ vasculature in rat renal analysis for ochratoxin a: relevance to toxicology of nephrotoxins.

Authors:  Peter Mantle; Mehmet A Kilic; Firdevs Mor; Ozlem Ozmen
Journal:  Toxins (Basel)       Date:  2015-03-24       Impact factor: 4.546

7.  Rat Kidney Cancers Determined by Dietary Ochratoxin A in the First Year of Life.

Authors:  Peter Mantle
Journal:  J Kidney Cancer VHL       Date:  2016-09-26

8.  Binding of ochratoxin A to a urinary globulin: a new concept to account for gender difference in rat nephrocarcinogenic responses.

Authors:  Peter G Mantle; Judit Nagy
Journal:  Int J Mol Sci       Date:  2008-05-08       Impact factor: 6.208

9.  A new ochratoxin A biodegradation strategy using Cupriavidus basilensis Őr16 strain.

Authors:  Szilamér Ferenczi; Mátyás Cserháti; Csilla Krifaton; Sándor Szoboszlay; József Kukolya; Zsuzsanna Szőke; Balázs Kőszegi; Mihály Albert; Teréz Barna; Miklós Mézes; Krisztina J Kovács; Balázs Kriszt
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.